臨床外科67巻11号

2012年10月発行

特集 外科医のための癌診療データ 臓器別最新データ 2．肺癌

肺癌の治療

著者： 池田徳彦¹

所属機関： ¹東京医科大学外科1講座

ページ範囲：P.55 - P.61

覚えておきたいデータ

◆肺癌は病期別に治療方針が大きく異なるため，正確な病期診断が必要である．

◆Ⅰ・Ⅱ期は手術が治療の中心で，必要に応じて術後補助化学療法を行う．Ⅲ期は化学放射線療法が主体であるが，ⅢA期の一部に手術が行われることがある．

◆Ⅳ期は薬物治療の適応である．肺癌の組織型とともにEGFR遺伝子変異の有無を検索し，陽性の場合はEGFRチロシンキナーゼ阻害薬を1次治療で用いることもある．

参考文献

1）日本肺癌学会（編）：臨床・病理　肺癌取扱い規約．第7版．金原出版，2010

2）Kato H, Ichinose Y, Ohta M, et al：A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350：1713-1721, 2004

3）Hamada C, Tanaka F, Ohta M, et al：Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23：4999-5006, 2005

4）Koike T, Yamato Y, Yoshiya K, et al：Intentional limited pulmonary resection for peripheral T1N0M0 small-sized lung cancer. J Thorac Cardiovasc Surg 125：924-928, 2003

5）Okada M, Nishio W, Sakamoto T, et al：Effect of tumor size on prognosis in patients with non-small cell lung cancer：the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 129：87-93, 2005

6）Okada M, Koike T, Higashiyama M, et al：Radical sublobar resection for small-sized non-small cell lung cancer：a multicenter study. J Thorac Cardiovasc Surg 132：769-775, 2006

7）澤端章好，淺村尚生，呉屋朝幸，他：2002年の肺癌治療例の全国集計に関する報告．肺癌49：975-987，2009

8）Sakata R, Fujii Y, Kuwano H：Thoracic and cardiovascular surgery in Japan during 2009：Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 59：636-667，2011

9）澤端章好，藤井義敬，淺村尚生，他：2004年肺癌外科切除例の全国集計に関する報告．肺癌50：875-888，2010

10）Arriagada R, Bergman B, Dunant A, et al：Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350：351-360, 2004

11）Winton T, Livingston R, Johnson D, et al：Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352：2589-2597, 2005

12）Douillard JY, Rosell R, De Lena M, et al：Adjuvant vinorelbine plus plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer（Adjuvant Navelbine International Trialist Association[ANITA]）：a randomized controlled trial. Lancet Oncol 7：719-727, 2006

13）Scagliotti GV, Fossati R, Torri V, et al：Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or ⅢA non-small cell lung cancer. J Natl Cancer Inst 95：1453-1461, 2003

14）Waller D, Peake MD, Stephens RJ, et al：Chemotherapy for patients with non-small cell lung cancer：the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26：173-182, 2004

15）Pignon JP, Tribodet H, Scagliotti GV, et al：Lung adjuvant cisplatin evaluation：a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26：3552-3559, 2008

16）Strauss GM, Herndon JE 2nd, Maddaus MA, et al：Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer：CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26：5043-5051, 2008

17）Albain KS, Swann RS, Rusch VW, et al：Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ non-small-cell lung cancer：a phase Ⅲ randomised controlled trial. Lancet 374：379-386, 2009

18）Mok TS, Wu YL, Thongprasert S, et al：Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 947-957, 2009

19）Mitsudomi T, Morita S, Yatabe Y, et al：Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label, randomised phase 3 trial. Lancet Oncol 11：121-128, 2010

20）Maemondo M, Inoue A, Kobayashi K, et al：Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362：2380-2388, 2010

21）Scagliotti GV, Parikh P, von Pawel J, et al：Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26：3543-3551, 2008

22）Scagliotti G, Hanna N, Fossella F, et al：The differential efficacy of pemetrexed according to NSCLC histology：a review of two Phase Ⅲ studies. Oncologist 14：253-263, 2009

23）Reck M, von Pawel J, Zatloukai P, et al：Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27：1227-1234, 2009

24）Sandler A, Gray R, Perry MC, et al：Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355：2542-2550, 2006

25）Sandler AB, Schiller JH, Gray R, et al：Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27：1405-1412, 2009

26）Kwak EL, Bang YJ, Camidge DR, et al：Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363：1693-1703, 2010